Eli Lilly Closes Acquisition of AtaiBeckley, Gains Depression Drug BPL-003
Image
Indianapolis – September 16, 2026 -- Eli Lilly and Company (NYSE: LLY) has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions.
Deal adds BPL-003 to Lilly's neuroscience pipeline for treatment-resistant depression
The acquisition brings Lilly control of AtaiBeckley's lead investigational program, BPL-003, targeting patients with treatment-resistant depression who have not responded to multiple prior therapies. AtaiBeckley shareholders approved the transaction at a special meeting held ahead of closing.